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Summary
Herpes simplex virus (HSV)-1 and -2 infections are highly prevalent worldwide. HSV 
infection during pregnancy can result in neonatal herpes infection, which is charac-
terized by lifelong infection with periods of latency and reactivation. HSV can be ac-
quired by an infant during one of three periods: in utero (5 %), peripartum (85 %), 
or postnatal (10 %). Neonatal HSV is a rare but significant infection that may be as-
sociated with severe morbidity and mortality, especially if there is dissemination or 
central nervous system involvement. Diagnostic and therapeutic advances have led to 
a reduction in mortality and, to a lesser extent, improvement of neurodevelopmental 
outcomes, but further developments are still needed. It is essential to improve the 
clinician's ability to identify infants who are at increased risk of HSV infection and to 
prevent mother-to-child transmission. The development of novel antiviral agents with 
higher efficacy is a worthwhile aim for the future.
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Introduction
Herpes simplex virus (HSV) is one of the most common se-
xually transmitted pathogens and is responsible for genital 
herpes infection. Both HSV-1 and HSV-2 can cause genital 
herpes as wells as neonatal infection via mother-to-child 
transmission, which can lead to serious health problems 
for the newborn [1]. Maternal infection with HSV before 
or during childbirth can cause neonatal infection through 
vertical transmission or close contact. Neonatal HSV infec-
tion refers to infection within 28 days of the neonatal peri-
od, including intrauterine infection (also known as innate 
infection), birth canal infection, and postnatal infection 
[2, 3]. In order to prevent and better control HSV infection 
of newborns, it is necessary to fully understand the preva-
lence, transmission mechanisms, influencing factors as well 
as prevention and control measures of HSV mother-to-child 
transmission.
Prevalence, incidence and burden of the 
disease
Maternal infection with HSV is very common and is associa-
ted with lifelong infection in both developed and developing 
countries. The prevalence varies from country to country, 
which is well illustrated by the fact that in Nigeria 99.4 % 
of pregnant women were seropositive for anti-HSV-1 and 
HSV-2 IgG antibodies, while in South Africa the seropre-
valence of HSV-2 infection was 58.7 %. Ethiopia had the 
lowest rate of African countries, with 32.1 % [4–6]. Similar 
to Ethiopia, the overall weighted prevalence of HSV-2 was 
31.4 % in Haiti, while in Korea, Kim et al. reported an HSV-
2 prevalence of 17 % [7, 8]. In the United States, between 
1989–2010, 53 % of pregnant women were seropositive for 
HSV-1, 9 % for HSV-2 and 15 % were seropositive for both 
[9]. A decrease in HSV-1 and HSV-2 infections was reported 
in Finland, where the HSV-1 positivity rate of sera decreased 
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from 69.5 % to 45 % over 20 years. The seroprevalence of 
HSV-2 decreased to a lesser extent, from 17.5 % to 11 % 
[10]. However, the authors found that 48 % of women of 
childbearing age were at risk of primary HSV infection du-
ring pregnancy. In the Netherlands, there is also a tendency 
towards decreasing HSV-1 and HSV-2 seroprevalence. In 
1995, the positivity rate of HSV-1 sera was 47.7 %, while 
for HSV-2 it was 6.8 %. By 2006, seropositivity of HSV-1 
had decreased to 42.7 %, while HSV-2 seropositivity was 
6.0 % [11]. In Germany, according to Korr et al., from 1997–
1999 to 2008–2011 HSV-1 seroprevalence decreased from 
82.1 % to 78.4 % while HSV-2 seroprevalence decreased 
from 13.3 % to 9.6 % (Table 1) [12]. This also means that 
an increasing number of adolescents lack protective antibo-
dies against HSV-1 at the beginning of their sexual life [13]. 
However, HSV-1 still causes primarily genital herpes. The 
main risk factors for genital HSV infection are having two or 
more sexual partners, history of other sexually transmitted 
disease(s), female gender, use of contraceptives, low educati-
onal level, belonging to a minority ethnic group and sexual 
activity at an early age [6, 14, 15].
In case of asymptomatic infection of the mother, the 
alarming clinical signs are missing, so that it is difficult to 
recognize an HSV infection in newborns; this can lead to 
serious health consequences. In Australia, the incidence of 
HSV infection in newborns was 3.27/100,000 live births. 
Of these, 62.7 % were caused by HSV-1 and 37.2 % by 
HSV-2 [16]. In the United States in 2006, the incidence 
of neonatal herpes was 9.6/100,000 live births [17], but 
among Malawian female adolescents the incidence was 
much higher, 71.8/100,000 live births [18]. According to 
Hemelaar et al., the incidence of neonatal herpes infections 
in the Netherlands was 4.7/100,000 births for the period 
2006–2011, which was twice as high as the incidences re-
ported in previous studies [19]. In one of the most recent 
studies [20], the estimated global incidence of neonatal her-
pes infection was 10.3/100,000 live births, with the largest 
number of cases in Africa, accounting for 37 % of the glo-
bal number of cases. However, the exact incidence is still 
not clear due to the lack of data on neonatal HSV infection 
(Table 2).
The mortality rate of neonatal herpes is high, even after 
intravenous acyclovir treatment, imposing a heavy burden on 
both the family and society. Treating neonatal herpes is ex-
pensive, and involves the costs of hospital stay, intensive care, 
intravenous drug therapy, laboratory tests, and the long-term 
costs of disability in case of severe neurological outcomes. 
According to Ambroggio et al., the cost of hospitalization 
was up to $37,431 per infant (quartile spacing: $14,667 to 
$74,519) [21].
Table 1 Prevalence of HSV1 & HSV2.
Year HSV1/HSV2 Country % seroprevalence Reference
– HSV1& HSV2 Nigeria 99.4 [4–6]
– HSV2 South Africa 58.7 [4–6]
– HSV2 Ethiopia 32.1 [4–6]
– HSV2 Haiti 31.4 [7, 8]
– HSV2 Korea 17 [7, 8]
1989–2010 HSV1 US 53 [9]
1989–2010 HSV2 US 9 [9]
1989–2010 HSV1& HSV2 US 15 [9]
1995 HSV1 Netherlands 47.7 [11]
1995 HSV2 Netherlands 6.8 [11]
2006 HSV1 Netherlands 42.7 [11]
2006 HSV2 Netherlands 6 [11]
1997–1999 HSV1 Germany 82.1 [12]
2008–2011 HSV1 Germany 78.4 [12]
1997–1999 HSV2 Germany 13.3 [12]
2008–2011 HSV2 Germany 9.6 [12]
–, not available.
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Clinical types of HSV infection
HSV-1 is predominantly associated with orolabial infection, 
but may be responsible for genital herpes as well. HSV-2 is 
almost exclusively sexually transmitted, causing genital her-
pes. However, the number of genital herpes infections trigge-
red by HSV-1 has increased during the past years [22]. Mo-
reover, Brown et al. reported that HSV-1 had a higher risk 
of mother-to-child transmission than HSV-2 [23]. Primary 
HSV infections in women are mainly asymptomatic, but can 
present as painful erythematous papules, followed by vesicles 
and finally erosions on the vulva, labia major and minor, va-
gina and cervix, lasting for approximately 8–10 days. Recur-
rent herpes may be asymptomatic or symptomatic.
Types of mother-to-child transmission 
and main risk factors for neonatal 
herpes infection
HSV mother-to-child transmission can take place in the 
uterus (in utero transmission), during delivery (peripartum 
neonatal transmission) and after birth (postnatal HSV in-
fection) [1, 24]. 85 % of mother-to-child HSV transmissions 
occur during the delivery stage, when there is viral shed-
ding from the genital tract – particularly in secretions from 
the vagina. During pregnancy, both hematogenous spread 
and vertical transmission can lead to placental or amniotic 
membrane involvement, resulting in intrauterine (congeni-
tal, antepartum) HSV transmission, which accounts for 
5 % of genital HSV infections. HSV can also be transmitted 
postnatally to the newborn, comprising 10 % of cases. Post-
partum infections occur via direct contact of the newborn 
with HSV-infected persons, mainly from the mother by kis-
sing, usually from her orolabial or cutaneous lesions. Ho-
wever, 70 % of mothers with HSV-infected newborns have 
no history, symptoms or signs of HSV infection at delivery 
[25]. A possible explanation is that recurrent genital her-
pes during pregnancy is more common than primary genital 
herpes, and recurrent genital herpes is often asymptomatic. 
According to Straface et al., nearly half of HSV infections 
in newborns were caused by the mother's recurrent genital 
herpes infection [26].
During pregnancy, the risk of transmission of primary 
genital herpes is higher than that of recurrent genital her-
pes. 30 % to 50 % of newborns are infected with HSV if 
the mother has a primary HSV infection in the third trimes-
ter [27]. In this case, there is not enough time for complete 
seroconversion to IgG before delivery and the infant is born 
without any protective passive IgG from the mother. The risk 
of neonatal infection is therefore highest at the time of the 
delivery. If a pregnant woman has primary HSV infection in 
the first trimester, her transmission efficiency is low; even if 
herpetic lesions can be observed in the genital area, the risk 
of neonatal infection is less than 1 % [2]. These data were 
confirmed by Brown et al., who found that of 177 HSV-po-
sitive and antibody-tested pregnancies, 26 pregnant women 
had primary genital herpes, and 151 had recurrent genital 
herpes at the time of delivery [28]. The results showed that 
the risk of neonatal herpes infection was 59.3 times as high 
for primary genital herpes than for recurrent genital herpes. 
Further analysis revealed that HSV transmission to new-
borns was due to primary genital herpes in 44.4 % of the 
cases, and by recurrent infections in 23.5 % of cases. The 
transmission rate of recurrent genital herpes from mother to 
child was only 1.3 %. Maternal HSV antibodies delivered to 
the fetus via the placenta have a protective effect. One major 
risk factor for HSV transmission from mother to child is the 
absence of maternal serum HSV antibody. The rupture time 
of the membrane is also closely related to transmission risk. 
Finger-Jardim et al. reported that if the time between rupture 
of membranes and delivery is more than six hours, the risk of 
retrograde infection from the cervix is approximately four-
fold [29]. For mothers with active herpes at the time of deli-
very, the risk of neonatal HSV infection can be significantly 
reduced if cesarean section is performed within four hours 
after rupture. If the rupture time is more than four hours, 
regardless of the mode of delivery, almost all newborns will 
be infected with HSV. In case of genital herpes symptoms 
during pregnancy, obstetricians would probably recommend 
cesarean section as the preferred mode of delivery. Studies 
that have sought to determine whether cesarean section can 
Table 2 Incidence of neonatal herpes.
Year Country Herpes simplex
Incidence (per 100,000)  
live births Reference
2006 USA Neonatal herpes 9.6 [17]
2010 Malawi Neonatal herpes 71.8 [18]
2006–2011 Netherlands Neonatal herpes 4.7 [19]
2010–2015 World Neonatal herpes 10.3 Africa highest (37 %) [20]
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really reduce the risk of neonatal HSV infection are limited, 
and most have not been properly conducted. According to 
some studies, cesarean section can reduce the risk of mother-
to-child HSV transmission [23, 30]. However, performing 
cesarean sections before membrane rupture cannot block the 
spread of HSV completely, due to the possibility of intraute-
rine transmission [31].
In addition to the main factors mentioned above, such as 
cervical HSV positivity, fetal skin integrity can also affect the 
efficiency of mother-to-child HSV transmission. Transmissi-
on is significantly higher if there is cervical HSV positivity. At 
the same time, invasive fetal monitoring and fetal examinati-
on can also increase the risk of infection [23].
Clinical manifestations of neonatal  
HSV infection
In case of in utero HSV transmission, a characteristic triad of 
cutaneous symptoms (vesicles, erosions, aplasia cutis, hyper- 
or hypopigmentation, scarring), neurological manifestations 
(hydranencephaly, microcephaly, intracranial calcifications, 
meningoencephalitis) and ophthalmologic symptoms (micro-
phthalmia, chorioretinitis, optic atrophy) can be observed. 
Both primary and recurrent maternal HSV infection can lead 
to in utero transmission of the virus [32, 33].
If administration of antiretroviral treatment is not timely 
in cases of neonatal herpes, the mortality rate is up to 60 %. 
Even cases of early use of acyclovir treatment may still result 
in serious disability [2].
According to clinical manifestations, neonatal HSV in-
fections acquired in the peripartum or postpartum period 
can be divided into three categories: the first is when the di-
sease is confined to the skin, eyes and lips (skin, eye, and/or 
mouth, referred to as SEM); the second is central nervous 
system infection and the third is disseminated infection. The 
timing of the first appearance of symptoms, the characteri-
stic findings, mortality rates and neurodevelopmental outco-
mes are summarized in Table 3. SEM disease is the mildest 
and accounts for 45 % of HSV infection in newborns. The 
central nervous system and other organs are not affected. 
[34]. Without treatment, HSV can easily lead to central 
nervous system infection or disseminated disease. Central 
nervous system infection constitutes 30 % of cases and only 
65 % of the newborns will have active cutaneous lesions. 
Cerebrospinal fluid examination will show mildly elevated 
white blood cells and a slight increase in protein [35, 36]. 
25 % of newborns have disseminated HSV infection. The 
infection can involve a variety of tissues and organs (such 
as brain, lung, liver, adrenal gland, skin, eyes and mouth), 
causing viral sepsis, respiratory failure, liver failure and dis-
seminated intravascular coagulation (DIC), but only 60 % of 
the infants have active cutaneous lesions [36]. Encephalitis is 
the most common complication, and fever is only present in 
a few cases [35].
Diagnosis of genital herpes infection
Both primary and recurrent herpes infections can be sym-
ptomatic (with prodromal symptoms) or asymptomatic. In 
case of clinical symptoms, not every patient will have typical 
cutaneous lesions (papules, vesicles and erosions) with local 
lymphadenopathy. Laboratory tests should therefore be per-
formed if a genital herpes infection is suspected.
Table 3 Clinical manifestations of neonatal HSV infection.
Skin, eye and mouth  
(SEM) symptoms
Central nervous system 
infection
Disseminated disease
First appearance of symptoms 10–12 days after birth 16–19 days after birth 10–12 days after birth
Characteristic symptoms Conjunctivitis, vesicles Epilepsy, lethargy, 
irritability, poor ap-
petite, unstable body 
temperature
Viral sepsis: respiratory failu-
re, liver failure, disseminated 
intravascular coagulation
Without intravenous acyclovir
1-year mortality rate – 50 % 85 %
Rate of normal neurodevelopment – 33 % 50 %
Use of intravenous acyclovir 60 mg/kg/day
1-year mortality rate – 4 % 29 %
Rate of normal neurodevelopment – 31 % 83 %
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Laboratory examination
To detect maternal infection, swabs should be taken from the 
mother's cervical and vaginal secretions or skin lesions. HSV 
DNA detection is now considered to be the gold standard for 
diagnosis. HSV DNA detection with PCR assays increases 
HSV detection rates significantly compared with virus cul-
ture, and the conditions for sample storage and transport 
are less stringent. If determination of anti-viral sensitivity 
is needed, cell culture should also be performed. In case of 
primary genital herpes, HSV typing should be done as well. 
Viral antigen detection methods are no longer recommended 
[37]. Type-specific serological tests can be used for detecting 
and monitoring HSV infection in pregnancy [38].
To confirm neonatal infection, isolation of HSV by 
culture is still the gold standard diagnostic method. Swabs 
should be taken 12–24 hours after birth from skin lesions, 
conjunctiva, mouth, nasopharynx and rectum [39].
Detection of HSV DNA from neonatal blood with PCR 
can confirm herpes simplex virus infection. In suspected 
central nervous system infection, cerebrospinal fluid (CSF) 
specimens can be cultured, or HSV DNA can be detected 
in neonatal CSF. The sensitivity of HSV DNA detection in 
CSF is higher than the sensitivity of virus culture; it is also 
suitable for HSV typing. It is therefore the preferred labora-
tory diagnostic method in cases of central nervous system 
infection [38].
Neonatal serum alanine aminotransferase (ALT) detecti-
on can be used in disseminated neonatal infection. It should 
be checked within 24 hours of birth; if ALT is twice as high 
as the upper limit of the normal range, neonatal disseminated 
infection can be suspected [24].
Treatment of maternal and neonatal 
herpes infections and prognosis of 
neonatal herpes infection
First episode of genital herpes
Primary genital herpes can cause severe genital ulcerations 
and neurologic involvement; every patient with first-episode 
genital herpes should therefore be treated. Pregnant women 
should be given intravenous acyclovir if they are severely in-
fected, but if they have positive HSV serology without a his-
tory of genital herpes, antiviral therapy is not recommended.
According to the latest treatment guidelines (2016) of the 
World Health Organization (WHO), the recommended regi-
me for the first episode of genital herpes is as follows [37, 40]:
	 oral acyclovir 400 mg, 3 times a day, for 10 days; or
	 oral acyclovir 200 mg, 5 times a day for 10 days; or
	 oral valacyclovir 500 mg twice daily for 10 days; or
	 oral famciclovir 250 mg 3 times daily for 10 days.
Recurrent genital herpes
Genital herpes recurrences usually cause minor symptoms, 
therefore decisions about therapy should be discussed with 
the patient. Oral acyclovir, famciclovir and valaciclovir can 
reduce the duration and severity of the symptoms. Treatment 
should be given within 24 hours of onset or in the prodromal 
phase.
WHO recommends [37, 40]:
	 oral acyclovir 400 mg, 3 times a day for 5 days; or
	 oral acyclovir 800 mg twice daily for 5 days; or
	 oral acyclovir 800 mg, 3 times a day for 2 days; or
	 oral valacyclovir 500 mg twice daily for 3 days; or
	 oral famciclovir 250 mg twice daily for 5 days.
Slight differences can be observed between the WHO 
guidelines and the latest recommendations of the US Centers 
for Disease Control and Prevention (CDC). The CDC recom-
mends [37, 41]:
	 oral acyclovir 400 mg, 3 times a day; or
	 oral valacyclovir 500 mg twice a day; taken from 36th 
week of pregnancy.
For pregnant women with frequent or severe genital her-
pes during pregnancy, WHO recommends long-term inhibi-
tory regimens [37, 40]:
	 oral acyclovir 400 mg twice daily or
	 valacyclovir 500 mg twice daily; or
	 famciclovir 250 mg twice daily for at least 6–12 months.
Treatment of neonates
In highly suspected or newly diagnosed neonatal HSV infec-
tions, immediate antiviral therapy should be administered. 
Early and effective antiviral therapy is the most critical factor 
affecting prognosis.
Treatment recommendations by the CDC are acyclovir 
20 mg/kg i.v. every 8 hours for 14 days for disease limited to 
the skin and mucous membranes, or for 21 days for dissemi-
nated or central nervous system infection [41]. After 21 days 
of treatment, re-analysis of the cerebrospinal fluid is needed. 
If HSV DNA test of the CSF is negative, treatment should 
come to an end – but if the test result is positive, continuous 
intravenous infusions should be given until the test result is 
negative.
Prognosis of neonates
Comparison of low-dose therapy (i.v. acyclovir 30 mg/kg/
day, every 8 hours) with high-dose acyclovir treatment (i.v. 
acyclovir 60 mg/kg/day every 8 hours) has shown that the 
higher dose can significantly improve the survival rate of 
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neonates with HSV infection. With high-dose acyclovir tre-
atment, Kimberlin et al. found a mortality rate at 24 months 
of 31 % with disseminated disease and 6 % with central 
nervous system infection [42]. With low-dose acyclovir, the 
mortality rate at 24 months was 61 % with disseminated 
infection and 19 % with central nervous system infection. 
High dose acyclovir can also reduce the incidence of severe 
HSV-related neurological sequelae. The probability of nor-
mal development at 12 months of age was 6.6 times higher 
with high-dose acyclovir than with lower doses. In the acute 
phase of neonatal HSV infection, oral acyclovir improves the 
prognosis of the disease. In central nervous system infection, 
intravenous acyclovir can reduce the occurrence of neurolo-
gical sequelae, and the chance of normal development of the 
nervous system is higher. It is therefore recommended to give 
oral acyclovir at a dose of 300 mg three times a day for six 
months after completion of intravenous therapy. However, 
long-term use of acyclovir may cause neutropenia in infants; 
the blood count should therefore be closely monitored during 
treatment, first at two weeks and then at four weeks after 
initiation of acyclovir. If the neutrophil count is normal, a 
monthly check is sufficient [43].
Prevention: improve mother-to-child 
transmission strategy
Prevention of infection during pregnancy
Pregnant women who are not infected with genital herpes 
should avoid sexual intercourse or genital contact during the 
third trimester with a partner who has known or suspected 
genital herpes. The preventive effect of antiviral therapy is 
unknown. There is no evidence that antiviral therapy reduces 
the risk of HSV infection of pregnant women, and it is not 
recommended for prevention.
The WHO and US CDC guidelines do not recommend 
routine HSV-2 serological screening for pregnant women. 
Although HSV vaccination may be the best way to prevent 
infection, it is still in the experimental stage. In the United 
States, population trials have been conducted to evaluate the 
effect of recombinant gD2 subunit vaccines. Recent studies 
have found that gV2 vaccination of women who are not in-
fected with HSV can reduce the spread of HSV-1 and the risk 
of HSV-1-related genital herpes infection, but has no signifi-
cant preventive effect on HSV-2 [44].
Reducing the efficiency of mother-to-child transmission 
includes reducing the risk of in utero, peripartum and post-
natal virus transmission. Antiviral therapy may reduce the 
occurrence of genital lesions at the time of delivery, reduce 
the need for caesarean delivery and help to prevent postpar-
tum infection. Since 85 % of neonatal infections occur du-
ring the delivery phase, prevention should focus on avoiding 
exposure of newborns to genital herpes lesions and shed 
viruses during birth. The US CDC has suggested that all 
pregnant women should be asked before labor whether they 
have symptoms related to genital herpes (including prodro-
mal symptoms), and should be carefully checked for herpetic 
skin lesions. Performing a cesarean section before rupture of 
the membrane is the best protection against HSV infection 
if genital herpetic lesions are present. If there are no genital 
herpes or prodromal symptoms, cesarean section is not re-
commended. It should be emphasized that cesarean section 
cannot completely block the spread of HSV, because intrau-
terine infection is also possible.
Antiviral therapy can effectively reduce the recurrence 
rate of prenatal genital herpes and the probability of inocu-
lation during the delivery stage, and this helps to reduce the 
risk of mother-to-child transmission during cesarean section. 
However, data regarding the efficacy of antiviral therapy in 
reducing the incidence of neonatal infection are still lacking 
and further studies are needed. It is worth mentioning that 
in the last five years, intensive work has been carried out on 
the development of an HSV-2 vaccine. This should reduce 
HSV 2 infection and the probability of viral transmission. 
Such studies are currently undergoing Phase 1 and Phase 2 
clinical trials [44]. 10 % of HSV infections occur after birth, 
and may be due to transmission from a healthcare worker 
or family member [35]. HSV causes labial as well as genital 
herpes, and herpetic vesicles can appear on the hands as well. 
Virus can be also transmitted to newborns by caring, kissing, 
and touching. It is therefore recommended that mothers with 
known or suspected labial or genital herpes avoid close con-
tact with newborns.
Conclusions
HSV mother-to-child transmission is uncommon, but can 
cause serious harm to the newborn. Because HSV pro-
phylactic and therapeutic vaccines are still in the research 
stage, prevention of maternal infection, early detection and 
early antiviral therapy are still the main measures for the pre-
vention of HSV mother-to-child transmission. Prevention of 
maternal infection should focus on the prevention of new in-
fections in late pregnancy. Furthermore, in cases of first-epi-
sode genital herpes or recurrent episodes of genital herpes 
during pregnancy, standardized antiviral treatment should 
be initiated and caesarean section is advisable. Mothers with 
herpetic lesions should avoid close contact with the newborn.
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